Profile data is unavailable for this security.
About the company
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
- Revenue in USD (TTM)513.02m
- Net income in USD-68.63m
- Incorporated1975
- Employees1.95k
- LocationInotiv Inc2701 Kent AveWEST LAFAYETTE 47906-1350United StatesUSA
- Phone+1 (317) 463-4527
- Fax+1 (765) 497-1102
- Websitehttps://www.inotiv.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transcode Therapeutics Inc | 0.00 | -27.16m | 9.22m | 7.00 | -- | 5.88 | -- | -- | -354.09 | -354.09 | 0.00 | 1.71 | 0.00 | -- | -- | 0.00 | -592.26 | -153.21 | -1,387.56 | -219.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.49 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 5.20m | -42.68m | 9.60m | 52.00 | -- | 0.299 | -- | 1.85 | -22.27 | -22.27 | 2.71 | 16.72 | 0.0596 | -- | -- | 99,903.84 | -48.95 | -46.54 | -58.33 | -52.20 | -- | -- | -821.58 | -1,666.52 | -- | -- | 0.00 | -- | -2.36 | 104.50 | 8.79 | -- | -39.55 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -10.09m | 9.73m | 16.00 | -- | 0.8659 | -- | -- | -5.87 | -5.87 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -60.63 | -- | -72.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 9.86m | 163.00 | -- | 0.0483 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.43m | 10.01m | 3.00 | -- | 2,901.23 | -- | -- | -0.0199 | -0.0199 | 0.00 | 0.00002 | 0.00 | -- | -- | 0.00 | -71.49 | 17.96 | -72.49 | 20.49 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -10.35 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -23.06m | 10.04m | 14.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0188 | 0.00 | -- | -- | 0.00 | -148.18 | -58.12 | -194.91 | -64.99 | -- | -- | -- | -- | -- | -- | 1.03 | -- | -- | -- | 60.12 | -- | -57.90 | -- |
| Imunon Inc | 0.00 | -14.33m | 10.50m | 25.00 | -- | 2.79 | -- | -- | -10.20 | -10.20 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -122.58 | -57.72 | -208.59 | -70.83 | -- | -- | -- | -7,752.42 | -- | -- | 0.00 | -- | -- | -- | 4.58 | -- | -38.98 | -- |
| Inotiv Inc | 513.02m | -68.63m | 10.80m | 1.95k | -- | 0.0793 | -- | 0.021 | -2.22 | -2.22 | 15.80 | 3.96 | 0.6609 | 12.27 | 6.76 | 263,765.60 | -8.84 | -18.23 | -15.66 | -23.64 | 23.58 | 26.43 | -13.38 | -27.50 | 0.2673 | -0.6134 | 0.75 | -- | 4.54 | 53.36 | 36.72 | -- | 21.79 | -- |
| Bioatla Inc | 0.00 | -64.71m | 10.89m | 61.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.5313 | 0.00 | -- | -- | 0.00 | -165.61 | -49.22 | -317.99 | -57.35 | -- | -- | -- | -3,690.17 | -- | -- | -- | -- | -- | 16.17 | 43.48 | -- | -- | -- |
| Soligenix Inc | 0.00 | -11.46m | 10.89m | 14.00 | -- | 1.40 | -- | -- | -3.66 | -3.66 | 0.00 | 0.7705 | 0.00 | -- | -- | 0.00 | -105.25 | -73.79 | -165.82 | -151.46 | -- | 22.19 | -- | -1,147.93 | -- | -- | 0.00 | -- | -85.78 | -51.89 | -34.62 | -- | -- | -- |
| KALA BIO Inc | 0.00 | -35.84m | 11.13m | 38.00 | -- | -- | -- | -- | -5.94 | -5.94 | 0.00 | -1.17 | 0.00 | -- | -- | 0.00 | -90.62 | -61.19 | -316.35 | -75.37 | -- | -- | -- | -1,732.87 | -- | -12.71 | 1.44 | -- | -- | -- | 8.74 | -- | -31.05 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -24.14m | 11.15m | 14.00 | -- | 0.4846 | -- | -- | -19.16 | -19.16 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -59.72 | -43.45 | -68.03 | -48.13 | -- | -- | -- | -- | -- | -- | 0.0083 | -- | -- | -- | 11.57 | -- | 22.47 | -- |
| Moleculin Biotech Inc | 0.00 | -41.36m | 11.26m | 17.00 | -- | -- | -- | -- | -55.88 | -55.88 | 0.00 | -13.60 | 0.00 | -- | -- | 0.00 | -189.07 | -49.52 | -254.72 | -54.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 26.89 | -- | -24.21 | -- |
| Longeveron Inc | 1.44m | -21.34m | 11.55m | 25.00 | -- | 1.14 | -- | 8.03 | -1.34 | -1.34 | 0.0909 | 0.4732 | 0.0632 | -- | 6.65 | 57,480.00 | -93.88 | -70.26 | -114.04 | -83.92 | 74.88 | 44.57 | -1,485.11 | -683.81 | -- | -- | 0.00 | -- | 237.38 | -15.76 | -10.86 | -- | 51.32 | -- |
| Ainos Inc | 113.04k | -14.96m | 12.15m | 44.00 | -- | 0.8304 | -- | 107.48 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
Data as of Feb 11 2026. Currency figures normalised to Inotiv Inc's reporting currency: US Dollar USD
14.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.22m | 3.56% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 985.74k | 2.87% |
| GSA Capital Partners LLPas of 31 Dec 2025 | 509.89k | 1.48% |
| UBS Securities LLCas of 31 Dec 2025 | 429.93k | 1.25% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 359.76k | 1.05% |
| Massar Capital Management LPas of 30 Sep 2025 | 350.00k | 1.02% |
| Vantage Point Financial LLCas of 31 Dec 2025 | 336.55k | 0.98% |
| Geode Capital Management LLCas of 30 Sep 2025 | 327.45k | 0.95% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 295.09k | 0.86% |
| Ennismore Fund Management Ltd.as of 31 Dec 2024 | 257.00k | 0.75% |
More ▼
Data from 31 Dec 2024 - 31 Dec 2025Source: FactSet Research Systems Inc.
